Fundraising Fox
Boston · 5 people tracked
Find your way into Ginkgo Bioworks
Sign up to see every warm intro you have to Ginkgo Bioworks
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ginkgo Bioworks team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Ginkgo Bioworks believes that biology represents one of the most important domains for innovation, underlying food production, medicine, and environmental systems. The company emphasizes that while modern education has shifted focus away from the biological world toward human-built technology, there is a critical need to redirect attention and resources toward biological engineering. By developing autonomous laboratory technology, Ginkgo seeks to democratize and accelerate bioengineering capabilities across multiple industries including pharmaceuticals, agriculture, and industrial biotechnology.
Source: firm website, verified Nov 8, 2026.
Team · 5 people
from the firm's website & curatedFocused on strategic partnerships, investments, and expanding Ginkgo's ecosystem with non-traditional customers; previously led software development and built out finance, people ops, IT, and infrastructure functions. Holds a PhD in EECS from MIT and degrees in Computer Science and Psychology from Stanford.
Responsible for Ginkgo's overall foundry technology strategy and direction. Holds a PhD in Biological Engineering from MIT and an MEngSc in Mechanical Engineering from University College Dublin.
Co-founder and CEO of Ginkgo Bioworks, leading the company's autonomous labs across biopharma, agriculture, and industrial biotech. Former Chair of the U.S. National Security Commission on Emerging Biotechnology. Holds B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering from MIT.
Ginkgo Fellow and MIT professor considered a father of synthetic biology; supports R&D for the Foundry and is an AAAS Fellow.
Co-founded Ginkgo Bioworks in 2008 and serves as President, COO, and board member. A longtime synthetic biology practitioner recognized by Forbes and Fast Company. Holds a B.S. in Computer Science from the University of Utah and a PhD in Biological Engineering from MIT.
Founder mafia
18 people who came through Ginkgo Bioworks went on to found or lead other companies.
+ 6 more
Frequently asked questions
- What sectors does Ginkgo Bioworks focus on?
- Ginkgo Bioworks focuses on Biotech, Deep Tech.
- Where is Ginkgo Bioworks located?
- Ginkgo Bioworks is headquartered in Boston, US.
Media · Podcasts & interviews
featuring the teamJason Kelly of Gingko Automates Labs to Accelerate Discovery
Grow Everything · Jason Kelly
Could Biology Be AI's Next Big Opportunity? | Ginkgo Bioworks ...
Global Money Talk · Jason Kelly
AI, China & Next Industrial Revolution | CEO Ginkgo Bioworks
Accelerate Bio · Jason Kelly
EP 02: Jason Kelly (CEO of Ginkgo Bioworks)
Accelerate Science Now · Jason Kelly
EP 02: Jason Kelly (CEO of Ginkgo Bioworks)
Accelerate Science Now · Jason Kelly · linkedin.com
Jason Kelly, CEO of Ginkgo Bioworks on No Priors podcast ...
River98 · Jason Kelly
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.